Surfactant from neonatal to pediatric ICU: Bench and bedside evidence

Minerva Anestesiologica

Volumn 80, Issue 12, 2014, Pages 1345-1356

  Boet, A ^a   Brat, R ^a   Aguilera, S S ^a   Tissieres, P ^a   De Luca, D ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Intensive care; Neonatal; Respiratory insufficiency; Surface active agents

Indexed keywords

SECRETORY PHOSPHOLIPASE A2; SURFACTANT; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; LUNG SURFACTANT;

ADULT RESPIRATORY DISTRESS SYNDROME; ASTHMA; BRONCHIOLITIS; CHILDHOOD DISEASE; CYSTIC FIBROSIS; EXTRACORPOREAL OXYGENATION; HUMAN; IMMUNOMODULATION; INTENSIVE CARE UNIT; LUNG ARTERY PRESSURE; LUNG DYSPLASIA; LUNG HEMORRHAGE; LUNG LAVAGE; MECONIUM; MECONIUM ASPIRATION; NEWBORN DISEASE; NEWBORN INTENSIVE CARE; NEWBORN MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; POINT OF CARE TESTING; PREMATURITY; PROTEIN DEPLETION; QUALITY CONTROL; RESPIRATORY FAILURE; REVIEW; TERM BIRTH; TRANSIENT TACHYPNEA OF THE NEWBORN; ADOLESCENT; CHILD; INFANT; INTENSIVE CARE; NEONATAL INTENSIVE CARE UNIT; NEWBORN; PEDIATRIC INTENSIVE CARE UNIT; PRESCHOOL CHILD; PROCEDURES; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RESPIRATORY INSUFFICIENCY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CRITICAL CARE; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; INTENSIVE CARE UNITS, PEDIATRIC; INTENSIVE CARE, NEONATAL; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RESPIRATORY INSUFFICIENCY;

EID: 84925458664     PISSN: 03759393     EISSN: 18271596     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Morley CJ, Davis JA. Artificial surfactant therapy. Lancet 1980;1:252.
2. Sürmeli-Onay Ö, Korkmaz A, Yigit S, Yurdakök M. Surfactant therapy in late preterm infants: respiratory distress syndrome and beyond. Turk J Pediatr 2012;54:239-46.
3. Altman M, Vanpée M, Cnattingius S, Norman M. Risk factors for acute respiratory morbidity in moderately preterm infants. Paediatr Perinat Epidemiol 2013;27:172-81.
4. Li Y, Marcoux MO, Gineste M, Vanpee M, Zelenina M, Casper C. Expression of water and ion transporters in tracheal aspirates from neonates with respiratory distress. Acta Paediatr 2009;98:1729-37.
5. Machado LU, Fiori HH, Baldisserotto M, Ramos Garcia PC, Vieira AC, Fiori RM. Surfactant deficiency in transient tachypnea of the newborn. J Pediatr 2011;159:750-4.
6. Tsuda H, Takahashi Y, Iwagaki S, Uchida Y, Kawabata I, Hayakawa M et al. Amniotic lamellar body counts can predict the occurrence of respiratory distress syndrome as well as transient tachypnea of the newborn (TTN). J Perinat Med 2011;39:245-50.
7. Piazze J, Cerekja A. Lamellar bodies: platelet channel particles as predictors of respiratory distress syndrome (RDS) and of transient tachypnea of the newborn. J Perinat Med 2011;39:349-51.
8. Fiori HH, Henn R, Baldisserotto M, Bica IG, Fiori RM. Evaluation of surfactant function at birth determined by the stable microbubble test in term and near term infants with respiratory distress. Eur J Pediatr 2004;163:443-8.
9. Nguyen S, Kuschel C, Teele R, Spooner C. Water birth - a near-drowning experience. Pediatrics 2002;110(2 Pt 1):411-3.
10. Gilbert R. Water birth-a near-drowning experience. Pediatrics 2002;110(2 Pt 1):409.
11. Bowden K, Kessler D, Pinette M, Wilson E. Underwater birth: missing the evidence or missing the point? Pediatrics 2003;112:972-3.
12. Engle W, and the Committee on Fetus and Newborn of teh American Academy of Pediatrics. Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate. Pediatrics 2008;121:419.
13. López-Rodríguez E, Ospina OL, Echaide M, Taeusch TW, Pérez-Gil J. Exposure to Polymers Reverses Inhibition of Pulmonary Surfactant by Serum, Meconium, or Cholesterol in the Captive Bubble Surfactometer. Biophysical J 2012;103:1451-9.
14. Touqui L, Arbibe L. A role for phospholipase A2 in ARDS pathogenesis. Mol Med Tod 1999;5:244-9.
15. Hite RD, Seeds MC, Jacinto RB, Grier BL, Waite BM, Bass DA. Lysophospholipid and fatty acid inhibition of pulmonary surfactant: non-enzymatic models of phospholipase A2 surfactant hydrolysis. Biochim Biophys Acta 2005;1720:14-21.
16. De Luca D, Baroni S, Vento G, Piastra M, Pietrini D, Romitelli F et al. Secretory phospholipase A2 and neonatal respiratory distress: pilot study on broncho-alveolar lavage. Intensive Care Med 2008;34:1858-64.
17. Carnielli VP, Zimmermann LJ, Hamvas A, Cogo PE. Pulmonary surfactant kinetics of the newborn infant: novel insights from studies with stable isotopes. J Perinatol 2009;29(Suppl 2):S29-37.
18. Chabot S, Koumanov K, Lambeau G, Gelb MH, Balloy V, Chignard M et al. Inhibitory effects of surfactant protein-A on surfactant phosoholipid hydrolysis by secreted phospholipasesA2. J Immunol 2003;171:995-1000.
19. Berger A, Havet N, Vial D, Arbibe L, Dumarey C, Watson ML et al. Dioleylphosphatidylglycerol inhibits the expression of type II phospholipase A2 in macrophages. Am J Respir Crit Care Med 1999;159:613-8.
20. Willson DF, Notter RH. The future of exogenous surfactant therapy. Respir Care 2011;56:1369-86.
21. De Luca D, Minucci A, Trias J, Tripodi D, Conti G, Zuppi C et al. Study Group on Secretory Phospholipase in Pediatrics. Varespladib inhibits secretory phospholipase A2 in bronchoalveolar lavage of different types of neonatal lung injury. J Clin Pharmacol 2012;52:729-37.
22. De Luca D, Vendittelli F, Trias J, Fraser H, Minucci A, Gentile L et al. Surfactant and Varespladib Co-Administration in Stimulated Rat Alveolar Macrophages Culture. Curr Pharm Biotechnol 2013;14:445-8.
23. Levine CR, Gewolb IH, Allen K, Welch RW, Melby JM, Pollack S et al. The safety, pharmacokinetics, and antiinflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res 2005;58:15-21.
24. Curstedt T, Calkovska A, Johansson J. New generation synthetic surfactants. Neonatology 2013;103:327-30.
25. Tan K, Lai NM, Sharma A. Surfactant for bacterial pneumonia in late preterm and term infants. Cochrane Database Syst Rev 2012;2:CD008155.
26. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J Pediatr 1998;132:40-7.
27. Konduri GG, Sokol GM, Van Meurs KP, Singer J, Ambalavanan N, Lee T et al for the Neonatal Inhaled Nitric Oxide Study Group. Impact of early surfactant and inhaled nitric oxide therapies on outcomes in term/late preterm neonates with moderate hypoxic respiratory failure. J Perinatol 2013;33:944-9.
28. Herting E, Gefeller O, Land M, Van Sonderen L, Harms K, Robertson B. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics 2000;106:957-64; discussion 1135.
29. Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991;87:101-7.
30. Fetter WP, Baerts W, Bos AP, Van Lingen RA. Surfactant replacement therapy in neonates with respiratory failure due to bacterial sepsis. Acta Paediatr 1995;84:14-6.
31. Hintz SR, Suttner DM, Sheehan AM, Rhine WD, Van Meurs KP. Decreased use of neonatal extracorporeal membrane oxygenation (ECMO): how new treatment modalities have affected ECMO utilization. Pediatrics 2000;106:1339-43.
32. Holm BA, Notter RH. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J Appl Physiol 1987;63:1434-42.
33. Deodhar J, Kadam S, Pharande P, Vaidya U, Pandit A. Maternal blood aspiration: an unusual cause of respiratory distress in a neonate. Ann Trop Paediatr 2006;26:255-7.
34. Gordon E, South M, McDougall PN, Dargaville PA. Blood aspiration syndrome as a cause of respiratory distress in the newborn infant. J Pediatr 2003;142:200-2.
35. Wiswell TE. Expanded uses of surfactant therapy. Clin Perinatol 2001;28:695-711.
36. Strauss T, Rozenzweig N, Rosenberg N, Shenkman B, Livnat T, Morag I et al. Surfactant impairs coagulation invitro: A risk factor for pulmonary hemorrhage? Thromb Res 2013;132:599-603.
37. Findlay RD, Taeusch HW, David-Cu R. Walther FJ. Lysis of red blood cells and alveolar epithelial toxicity by therapeutic pulmonary surfactants. Pediatr Res 1995;37:26-30.
38. Pandit PB, Dunn MS, Colucci EA. Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics 1995;95:32-6.
39. Amizuka T, Shimizu H, Niida Y, Gawa Y. Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema. Eur J Pediatr 2003;162:697-702
40. Escande B, Kuhn P, Rivera S, Messer J. Secondary surfactant deficiencies [in French]. Arch Pediatr 2004;11:1351-9
41. Lacaze-Masmonteil T. Expanded use of surfactant therapy in newborns. Clin Perinatol 2007;34:179-89.
42. Yen TA, Wang CC, Hsieh WS, Chou HC, Chen CY, Tsao PN. Short-term outcome of pulmonary hemorrhage in very-low-birth-weight preterm infants. Pediatr Neonatol 2013;54:330-4.
43. Aziz A, Ohlsson A. Surfactant for pulmonary haemorrhage in neonates. Cochrane Database Syst Rev 2012;7:CD005254.
44. Van Ierland Y, De Beaufort AJ. Why does meconium cause meconium aspiration syndrome? Current concepts of MAS pathophysiology. Early Hum Dev 2009;85:617-20.
45. De Luca D, Minucci A, Zecca E, Piastra M, Pietrini D, Carnielli VP et al Bile acids cause secretory phospholipase A2 activity enhancement, revertible by exogenous surfactant administration. Intensive Care Med 2009;35:321-6.
46. Saugstad OD, Tølløfsrud PA, Lindenskov P, Drevon CA. Toxic effects of different meconium fractions on lung function: new therapeutic strategies for meconium aspiration syndrome? J Perinatol 2008;28(Suppl 3):S113-5.
47. Salvesen B, Stenvik J, Rossetti C, Saugstad OD, Espevik T, Mollnes TE. Meconium-induced release of cytokines is mediated by the TRL4/MD-2 complex in a CDl4-dependent manner. Mol Immunol. 2010;47:1226-34.
48. Romero R, Hyun Yoon B, Chaemsaithong P, Cortez J, Park CW, Gonzalez R et al. Secreted Phospholipase A2 is Increased in Meconium-Stained Amniotic Fluid of Term Gestations: Potential Implications for the Genesis of Meconium Aspiration Syndrome. J Matern Fetal Neonatal Med 2014;27:975-83.
49. De Luca D, Minucci A, Tripodi D, Piastra M, Pietrini D, Zuppi C et al Role of distinct phospholipases A2 and their modulators in meconium aspiration syndrome in human neonates. Intensive Care Med 2011;37:1158-65.
50. De Luca D, Cogo P, Zecca E, Piastra M, Pietrini D, Tridente A et al Intrapulmonary drug administration in neonatal and paediatric critical care: a comprehensive review. Eur Respir J 2011;37:678-89.
51. Soil RF, Dargaville P. Surfactant for meconium aspiration syndrome in full term infants. Cochrane Database Syst Rev 2000; CD002054
52. Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996;97:48-52.
53. Khammash H, Perlman M, Wojtulewicz J, Donn M. Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 1993;92:135-9.
54. Wiswell TE, Knight GR, Finer NN, Donn SM, Desai H, Walsh WF et al A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 2002;109:1081-7.
55. Chinese Collaborative Study Group for Neonatal Respiratory Distress. Treatment of severe meconium aspiration syndrome with porcine surfactant: a multicenter, randomized, controlled trial. Acta Paediatr. 2005;94:896-902.
56. El Shahed Al, Dargaville PA, Ohlsson A, Soil RF. Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane Database Syst Rev 2007;3:CD002054.
57. Dargaville PA, Copnell B, Mills JF, Haron I, Lee JK, Tingay DG et al lessMAS Trial Study Group. Randomized controlled trial of lung lavage with dilute surfactant for meconium aspiration syndrome. J Pediatr 2011;158:383-389. e2.
58. Dargaville PA, Copnell B, Mills JF, Haron I, Lee JK, Tingay DG et al lessMAS Trial Study Group. Fluid recovery during lung lavage in meconium aspiration syndrome. Acta Paediatr 2013;102:e90-3.
59. Finer NN. Surfactant use for neonatal lung injury: beyond respiratory distress syndrome. Paediatr Respir Rev. 2004;5(SupplA):S289-S297.
60. Dargaville PA, Mills JF, Copnell B, Loughnan PM, Mc-Dougall PN, Morley CJ. Therapeutic lung lavage in meconium aspiration syndrome: a preliminary report. J Paediatr Child Health 2007;43:539-45.
61. Gadzinowski J, Kowalska K, Vidyasagar D. Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO. J Perinatol 2008;28(Suppl 3):S56-66.
62. Lista G, Bianchi S, Castoldi F, Fontana P, Cavigioli F. Bronchoalveolar lavage with diluted porcine surfactant in mechanically ventilated term infants with meconium aspiration syndrome. Clin Drug Investig 2006;26:13-9.
63. Choi HJ, Hahn S, Lee J, Park BJ, Lee SM, Kim HS, Bae CW. Surfactant lavage therapy for meconium aspiration syndrome: a systematic review and meta-analysis. Neonatology 2012;101:183-91.
64. Hahn S, Choi HJ, Soil R, Dargaville PA. Lung lavage for meconium aspiration syndrome in newborn infants. Cochrane Database Syst Rev 2013;4:CD003486.
65. De Luca D, Piastra M, Tosi F, Pulitanò S, Mancino A, Genovese O et al Pharmacological therapies for pediatric and neonatal ALI/ARDS: an evidence-based review. Curr Drug Targets 2012;13:906-16.
66. Dahlem P, Van Aalderen WM, Bos AE Pediatric acute lung injury. Paediatr Respir Rev 2007;8:348-62.
67. Erickson S, Schibler A, Numa A, Nuthall G, Yung M, Pascoe et al. Acute lung injury in pediatric intensive care in Australia and New Zealand: A prospective, multicenter, observational study. Pediatr Crit Care Med 2007;8:317-23.
68. Randolph AG. Management of acute lung injury and acute respiratory distress syndrome in children. Crit Care Med 2009;37:2448-54.
69. De Luca D, Piastra M, Chidini G, Tissieres P, Calderini E, Essouri S et al. Respiratory Section of the European Society for Pediatric Neonatal Intensive Care (ESPNlC). The use of the Berlin definition for acute respiratory distress syndrome during infancy and early childhood: multicenter evaluation and expert consensus. Intensive Care Med 2013;39:2083-91.
70. De Luca D, Piastra M, Chidini G, Tissieres P, Calderini E, Essouri S et al. Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants. Crit Care 2013;17:R163.
71. Determann RM, Millo JL, Waddy S, Lutter R, Garrard CS, Schultz MJ. Plasma CO 6 levels are associated with development of ALI/ARDS in patients with ventilatorassociated pneumonia: a retrospective observational study. BMC Pulm Med 2009:9:49.
72. Kropski JA, Fremont RD, Calfee CS, Ware LB. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest 2009;135:1440-7.
73. Jorens PG, Sibille Y, Goulding NJ, Van Overveld FJ, Herman AG, Bossaert L et al. Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury. Eur Respir J 1995;8:1647-53.
74. Wang SZ, Rosenberger CL, Bao YX, Stark JM, Harrod KS. Clara cell secretory protein modulates lung inflammatory and immune responses to respiratory syncytial virus infection. J Immunol 2003;171:1051-60.
75. Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982;70:673-83.
76. Pison U, Seeger W, Buchhorn R, Joka T, Brand M, Obertacke U et al. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 1989;140:1033-9.
77. Gregory TJ, Longmore WJ, Moxley MA, Whitsett JA, Reed CR, Fowler AA 3rd et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991;88:1976-81.
78. Günther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996;153:176-84.
79. Schmidt R, Meier U, Yabut-Perez M, Walmrath D, Grimminger F, Seeger W et al. Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. Am J Respir Crit Care Med 2001;163:95-100.
80. Greene KE, Wright JR, Steinberg KP, Ruzinski JT, Caldwell E, Wong WB et al. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999;160:1843-50.
81. López-Rodríguez E, Ospina OL, Echaide M, Taeusch HW, Pérez-Gil J. Exposure to polymers reverses inhibition of pulmonary surfactant by serum, meconium, or cholesterol in the captive bubble surfactometer. Biophys J 2012;103:1451-9.
82. Simonato M, Baritussio A, Ori C, Vedovelli L, Rossi S, Dalla Massara L et al. Disaturated-phosphatidylcholine and surfactant protein-B turnover in human acute lung injury and in control patients. Respir Res 2011;12:36.
83. Woerndle S, Bartmann P. The effect of three surfactant preparations on in vitro lymphocyte function. J Perinat Med 1994;22:119-28.
84. Taut FJ, Rippin G, Schenk P, Findlay G, Wurst W, Hafner D et al. A Search for subgroups of patients with ARDS who may benefit from urfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). Chest 2008;134:724-32.
85. Schrama AJ, Elferink JG, Hack CE, De Beaufort AJ, Berger HM, Walther FJ. Pulmonary secretory phospholipase A2 in infants with respiratory distress syndrome stimulates in vitro neutrophil migration. Neonatology 2010;97:1-9.
86. Granata F, Frattini A, Loffredo S, Del Prete A, Sozzani S, Marone G et al. Signaling events involved in cytokine and chemokine production induced by secretory phospholipase A2 in human lung macrophages. Eur J Immunol 2006;36:1938-50.
87. El Hanache A, Gourrier E, Karoubi P, Merbouche S, Mouchnino G, Leraillez J. Modification of C-reactive protein after instillation of natural exogenous surfactants. Arch Pediatr 1997;4:27-31.
88. Hermon MM, Golej J, Burda G, Boigner H, Stoll E, Vergesslich K et al. Surfactant therapy in infants and children: three years experience in a pediatric intensive care unit. Shock 2002;17:247-51.
89. Herting E, Moller O, Schiffmann JH, Robertson B et al. Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome. Acta Paediatr 2002;91:1174-8.
90. Onarheim H, Vik V. Porcine surfactant (Curosurf) for acute respiratory failure after near-drowning in 12 years old. Acta Anaesthesiol Scand 2004;48:778-81.
91. Marx M, Golej J, Fürst G, Hermon M, Trittenwein G. Exogenous surfactant and high frequency oscillatory ventilation in a child with severe adult respiratory distress after near-drowning. Wien Klin Wochenschr 1995;107:146-8.
92. Moller JC, Schaible TF, Reiss I, Artlich A, Gortner L. Treatment of severe nonneonatal ARDS in children with surfactant and nitric oxide in a 'pre-ECMO'-situation. Int J Artif Organs 1995;18:598-602.
93. Suzuki H, Ohta T, Iwata K, Yamaguchi K, Sato T. Surfactant therapy for respiratory failure due to near-drowning. Eur J Pediatr 1996;155:383-4.
94. Tegtmeyer FK, Moller J, Zabel P. Inhibition of granulocyte activation by surfactant in a 2-yr-old female with meningococcusinduced ARDS. Eur Respir J 2002;19:776-9.
95. Duffett M, Choong K, Ng V, Randolph A, Cook DJ. Surfactant therapy for acute respiratory failure in children: a systematic review and metaanalysis. Critical Care 2007;11:R66.
96. Adhikari N, Burns KE, Meade MO. Pharmacologic treatments for acute respiratory distress syndrome and acute lung injury: systematic review and meta-analysis. Treat Respir Med 2004;3:307-28.
97. Zhang LN, Sun JP, Xue XY, Wang JX. Exogenous pulmonary surfactant for acute respiratory distress syndrome in adults: A systematic review and meta-analysis. Exp Ther Med 2013;5:237-242.
98. Ventre K, Haroon M, Davison C. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database Syst Rev 2006;3:CD005150.
99. Raghavendran K, Willson D, Notter RH. Surfactant therapy for acute lung injury and acute respiratory distress syndrome. Crit Care Clin 2011;27:525-59.
100. Markart P, Ruppert C, Wygrecka M, Colaris T, Dahal B, Walmrath D et al. Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. Thorax 2007;62:588-94.
101. Balaraman V, Meister J, Ku TL, Sood SL, Tam E, Killeen J et al. Lavage administration of dilute surfactants after acute lung injury in neonatal piglets. Am J Respir Crit Care Med 1998;158:12-7.
102. Balaraman V, Sood SL, Finn KC, Hashiro G, Uyehara CF, Easa D. Physiologic response and lung distribution of lavage versus bolus Exosurf in piglets with acute lung injury. Am J Respir Crit Care Med 1996;153:1838-43.
103. Balaraman V, Meister J, Ku TL, Sood SL, Tam E, Killeen J et al. Lavage administration of dilute surfactants after acute lung injury in neonatal piglets. Am J Respir Crit Care Med 1998;158:12-7.
104. Meister JC, Balaraman V, Ku T, De Silva A, Sood S, Uyehara CF et al. Lavage administration of dilute recombinant surfactant in acute lung injury in piglets. Pediatr Res 2000;47:240-5.
105. Rooney SA. The surfactant system and lung phospholipid biochemistry. Am Rev Respir Dis 1985;131:439-60.
106. Wright JR, Clements JA. Metabolism and turnover of lung surfactant. Am Rev Respir Dis 1987;136:426-44.
107. Van Golde LM, Batenburg JJ, Robertson B. The pulmonary surfactant system: Biochemical aspects and functional significance. Physiol Rev 1988;68:374-455.
108. European Respiratory Society Task Force on bronchoalveolar lavage in children. Bronchoalveolar lavage in children. Eur Respir J 2000;15:217-31.
109. Marraro GA, Luchetti M, Spada C, Galassini E, Giossi M, Piero AM. Selective medicated (normal saline and exogenous surfactant) bronchoalveolar lavage in severe aspiration syndrome in children. Pediatr Crit Care Med 2007;8:476-81.
110. Erpenbeck VJ, Krug N, Hohlfeld JM. Therapeutic use of surfactant components in allergic asthma. Naunyn Schmiedebergs Arch Pharmacol 2009;379:217-24.
111. Hite RD, Seeds MC, Bowton DL, Grier BL, Safta AM, Balkrishnan R et al. Surfactant phospholipid changes after antigen challenge: a role for phosphatidylglycerol in dysfunction. Am J Physiol Lung Cell Mol Physiol 2005;288:L6l0-7.
112. Cochrane CG. Pulmonary surfactant in allergic inflammation: new insights into the molecular mechanisms of surfactant function. Am J Physiol Lung Cell Mol Physiol 2005;288:L608-9.
113. Wang Y, Voelker DR, Lugogo NL, Wang G, Floros J, Ingram JL et al. Surfactant protein A is defective in abrogating inflammation in asthma. Am J Physiol Lung Cell Mol Physiol 2011;301:L598-606.
114. Erpenbeck VJ, Fischer I, Wiese K, Schaumann F, Schmiedl A, Nassenstein C et al. Therapeutic surfactants modulate the viability of eosinophils and induce inflammatory mediator release. Int Arch Allergy Immunol 2009;149:333-42.
115. Bhandari A, McGrath-Morrow S. Long-term pulmonary outcomes of patients with bronchopulmonary dysplasia. Semin Perinatol 2013;37:132-7.
116. Cogo PE, Toffolo GM, Gucciardi A, Benetazzo A, Cobelli C, Carnielli VP. Surfactant disaturated phosphatidylcholine kinetics in infants with bronchopulmonary dysplasia measured with stable isotopes and a two-compartment model. J Appl Physiol 2005;99:323-9.
117. Zimmermann LJ, Janssen DJ, Tibboel D, Hamvas A, Carnielli VP. Surfactant metabolism in the neonate. Biol Neonate 2005;87:296-307.
118. Merrill JD, Ballard RA, Cnaan A, Hibbs AM, Godinez RI, Godinez MH et al. Dysfunction of pulmonary surfactant in chronically ventilated premature infants. Pediatr Res 2004;56:918-26.
119. Schmölzer GM, Kumar M, Pichler G, Aziz K, O'Reilly M, Cheung PY. Non-invasive versus invasive respiratory support in preterm infants at birth systematic review and meta-analysis. BMJ 2013:347:6980
120. Barreira ER, Precioso AR, Bousso A. Pulmonary surfactant in respiratory syncytial virus bronchiolitis: the role in pathogenesis and clinical implications. Pediatr Pulmonol 2011;46:415-420
121. Dargaville PA, South M, McDougall PN. Surfactant abnormalities in infants with severe viral bronchiolitis. Arch Dis Child 1996;75:133-6.
122. Jat KR, Chawla D. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database Syst Rev 2012;9:CD009194.
123. Eber E. Treatment of acute viral bronchiolitis. Open Microbiol J 2011;5:159-64.
124. Kotecha S, Doull I, Davies P, McKenzie Z, Madsen J, Clark HW et al. Functional heterogeneity of pulmonary surfactant protein-D in cystic fibrosis. Biochim Biophys Acta 2013;1832:2391-400.
125. Jain D, Atochina-Vasserman EN, Tomer Y, Kadire H, Beers ME Surfactant protein D protects against acute hyperoxic lung injury. Am J Respir Crit Care Med 2008;178:805-13.
126. Griese M, Heinrich S, Ratjen F, Kabesch M, Paul K, Ballmann M et al. Surfactant protein a in cystic fibrosis: supratrimeric structure and pulmonary outcome. PLoS One 2012;7:e51050.
127. Wu Y, Raymond B, Goossens PL, Njamkepo E, Guiso N, Paya M et al. Type-IIA secreted phospholipase A2 is an endogenous antibiotic-like protein of the host. Biochimie 2010;92:583-7.
128. Scottish Intercollegiate Guidelines Network. SIGN50:a guideline developers handbook. [Internet]. Available from www.sign. ac.uk/guidelines/fulltext/50/[cited 2010, Feb. 13].